<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3134">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431300</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00022334</org_study_id>
    <secondary_id>CG 10011</secondary_id>
    <nct_id>NCT01431300</nct_id>
  </id_info>
  <brief_title>Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants</brief_title>
  <official_title>Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography
      of the central veins of the chest, and to determine whether dose reduction can be performed
      while maintaining image quality. This will be a prospective randomized study, in which
      healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram
      (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar.
      Quantitative and qualitative analysis will be performed on the images.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Imaging Quality Score</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two radiologists assessed imaging quality of each central venous segment for each patient, in order to compare imaging quality between each of the three doses administered. The visualization score for each venous segments was as follows:
poor / nondiagnostic
adequate
good
excellent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative Analysis Noise Ratios</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signal-to-noise and contrast-to-noise ratios were calculated for each central venous segment, to determine the magnitude of difference in each of the three administered doses. The ratio's were calculated as follows:
Signal-to-noise ratio: signal intensity of vessel segment / standard deviation of signal intensity of the background.
Contrast-to-noise ratio = (signal intensity of vessel segment minus signal intensity of adjacent muscle) / standard deviation of signal intensity of the background.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>0.03 mmol/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA-approved dose for lower extremity arterial imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.02 mmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.01 mmol/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadofosveset</intervention_name>
    <description>Intravenous administration of the specified dosage of gadolinium contrast agent</description>
    <arm_group_label>0.03 mmol/kg</arm_group_label>
    <arm_group_label>0.02 mmol/kg</arm_group_label>
    <arm_group_label>0.01 mmol/kg</arm_group_label>
    <other_name>Ablavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male or female subjects between 18-45 years of age

        Exclusion Criteria:

          -  Pregnant and lactating females

          -  known renal impairment

          -  allergy to gadolinium-based contrast

          -  metallic implanted devices

          -  claustrophobia.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Y Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>October 20, 2013</lastchanged_date>
  <firstreceived_date>September 7, 2011</firstreceived_date>
  <firstreceived_results_date>August 1, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central veins</keyword>
  <keyword>thorax</keyword>
  <keyword>superior vena cava</keyword>
  <keyword>Central vein imaging</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.01 mmol/kg of Gadofosveset</title>
          <description>Intravenous administration of gadofosveset via power injector at onset of MRI image acquisition</description>
        </group>
        <group group_id="P2">
          <title>0.02 mmol/kg of Gadofosveset</title>
          <description>Intravenous administration of gadofosveset via power injector at onset of MRI image acquisition</description>
        </group>
        <group group_id="P3">
          <title>0.03 mmol/kg of Gadofosveset</title>
          <description>Intravenous administration of gadofosveset via power injector at onset of MRI image acquisition. This is the FDA-approved dose for lower extremity arterial imaging</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">One subject with indeterminate pregnancy test, subject declined to proceed</participants>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.01 mmol/kg</title>
          <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
        </group>
        <group group_id="B2">
          <title>0.02 mmol/kg</title>
          <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
        </group>
        <group group_id="B3">
          <title>0.03 mmol/kg</title>
          <description>FDA-approved dose for lower extremity arterial imaging
gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="31"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="22.2" spread="5.3"/>
                <measurement group_id="B2" value="24.6" spread="8.1"/>
                <measurement group_id="B3" value="24.1" spread="7.5"/>
                <measurement group_id="B4" value="23.4" spread="6.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="9"/>
                <measurement group_id="B4" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Imaging Quality Score</title>
        <description>Two radiologists assessed imaging quality of each central venous segment for each patient, in order to compare imaging quality between each of the three doses administered. The visualization score for each venous segments was as follows:
poor / nondiagnostic
adequate
good
excellent</description>
        <time_frame>14 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>0.01 mmol/kg</title>
            <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
          </group>
          <group group_id="O2">
            <title>0.02 mmol/kg</title>
            <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
          </group>
          <group group_id="O3">
            <title>0.03 mmol/kg</title>
            <description>FDA-approved dose for lower extremity arterial imaging
gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Imaging Quality Score</title>
            <description>Two radiologists assessed imaging quality of each central venous segment for each patient, in order to compare imaging quality between each of the three doses administered. The visualization score for each venous segments was as follows:
poor / nondiagnostic
adequate
good
excellent</description>
            <units>Units on a visualization score scale</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O2" value="2.1" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O3" value="2.3" lower_limit="1" upper_limit="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Analysis Noise Ratios</title>
        <description>Signal-to-noise and contrast-to-noise ratios were calculated for each central venous segment, to determine the magnitude of difference in each of the three administered doses. The ratio's were calculated as follows:
Signal-to-noise ratio: signal intensity of vessel segment / standard deviation of signal intensity of the background.
Contrast-to-noise ratio = (signal intensity of vessel segment minus signal intensity of adjacent muscle) / standard deviation of signal intensity of the background.</description>
        <time_frame>14 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>0.01 mmol/kg</title>
            <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
          </group>
          <group group_id="O2">
            <title>0.02 mmol/kg</title>
            <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
          </group>
          <group group_id="O3">
            <title>0.03 mmol/kg</title>
            <description>FDA-approved dose for lower extremity arterial imaging
gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quantitative Analysis Noise Ratios</title>
            <description>Signal-to-noise and contrast-to-noise ratios were calculated for each central venous segment, to determine the magnitude of difference in each of the three administered doses. The ratio's were calculated as follows:
Signal-to-noise ratio: signal intensity of vessel segment / standard deviation of signal intensity of the background.
Contrast-to-noise ratio = (signal intensity of vessel segment minus signal intensity of adjacent muscle) / standard deviation of signal intensity of the background.</description>
            <units>ratio</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>signal to noise ratio</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81" spread="17"/>
                  <measurement group_id="O2" value="119" spread="28"/>
                  <measurement group_id="O3" value="135" spread="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>contrast to noise ratio</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37" spread="14"/>
                  <measurement group_id="O2" value="60" spread="28"/>
                  <measurement group_id="O3" value="80" spread="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>signal-to-noise (SNR) ratios of the central veins in the 0.01 mmol/kg and 0.03mmol/kg dose groups were compared.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>54</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>contrast-to-noise (CNR) ratios of the central veins in the 0.01 mmol/kg and 0.03mmol/kg dose groups were compared.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>43</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>0.01 mmol/kg</title>
          <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
        </group>
        <group group_id="E2">
          <title>0.02 mmol/kg</title>
          <description>gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
        </group>
        <group group_id="E3">
          <title>0.03 mmol/kg</title>
          <description>FDA-approved dose for lower extremity arterial imaging
gadofosveset : Intravenous administration of the specified dosage of gadolinium contrast agent</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Kim</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-7284</phone>
      <email>charles.kim@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
